Cellosaurus logo
expasy logo

Cellosaurus SK-MEL-93 DX-2 (CVCL_5652)

[Text version]
Cell line name SK-MEL-93 DX-2
Synonyms SK-MEL-93-DX-2; SK-MEL-93 DX2; SK-MEL-93 (DX2); DX-2; DX2; SK-MEL-93(2); SK-MEL-93-2; DX-Mel-2
Accession CVCL_5652
Secondary accession CVCL_6062
Resource Identification Initiative To cite this cell line use: SK-MEL-93 DX-2 (RRID:CVCL_5652)
Comments From: Memorial Sloan Kettering Cancer Center; New York; USA.
Derived from site: Metastatic; Hypodermis; UBERON=UBERON_0002072.
Sequence variations
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_5651 ! SK-MEL-93 DX-1
CVCL_5650 ! SK-MEL-93 DX-3
CVCL_A432 ! SK-MEL-93 DX-4
CVCL_A433 ! SK-MEL-93 DX-5
CVCL_A434 ! SK-MEL-93 DX-6
CVCL_A435 ! SK-MEL-93 DX-B
Sex of cell Female
Age at sampling 71Y
Category Cancer cell line
Publications

PubMed=6976407; DOI=10.1084/jem.154.6.1764; PMCID=PMC2186539
Albino A.P., Lloyd K.O., Houghton A.N., Oettgen H.F., Old L.J.
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient Implications for the study of tumor antigens.
J. Exp. Med. 154:1764-1778(1981)

PubMed=7017212; DOI=10.1093/jnci/66.6.1003
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
J. Natl. Cancer Inst. 66:1003-1012(1981)

PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084
Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F., Old L.J.
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
J. Exp. Med. 158:53-65(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=2983346; DOI=10.1073/pnas.82.5.1470; PMCID=PMC397284
Dracopoli N.C., Houghton A.N., Old L.J.
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985)

PubMed=3081645; DOI=10.4049/jimmunol.136.7.2534
Panneerselvam M., Welt S., Old L.J., Vogel C.-W.
A molecular mechanism of complement resistance of human melanoma cells.
J. Immunol. 136:2534-2541(1986)

PubMed=2886213
Dracopoli N.C., Alhadeff B., Houghton A.N., Old L.J.
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma.
Cancer Res. 47:3995-4000(1987)

PubMed=1716514
Albino A.P., Davis B.M., Nanus D.M.
Induction of growth factor RNA expression in human malignant melanoma: markers of transformation.
Cancer Res. 51:4815-4820(1991)

PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N
Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C., Fountain J.W.
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Genes Chromosomes Cancer 22:157-163(1998)

Cross-references
Encyclopedic resources Wikidata; Q54954340
Polymorphism and mutation databases Cosmic; 721817
Cosmic; 926001
Cosmic; 933120
Entry history
Entry creation04-Apr-2012
Last entry update19-Dec-2024
Version number16